Metformin is a widely prescribed oral medication used to manage blood glucose levels in adults with type 2 diabetes. It belongs to the therapeutic class of Diabetes Management drugs and is available in pill form at strengths of 500 mg, 850 mg, and 1000 mg. In Hong Kong, metformin is a prescription (Rx) product that is regulated by the Department of Health and follows international standards set by agencies such as the U.S. FDA. The medication is marketed under numerous brand names, but the active ingredient remains the same: metformin hydrochloride.
Metformin belongs to the biguanide class of antihyperglycemic agents. Its primary actions are:
These mechanisms together lower fasting and post-prandial blood glucose levels, helping patients achieve target glycated hemoglobin (HbA1c) values. Metformin has a rapid onset of action, with noticeable glucose-lowering effects within a few days, and a steady-state effect reached after about one week of consistent dosing. Oral bioavailability is approximately 50-60 %, and the drug is eliminated unchanged by the kidneys.
Metformin is approved by major regulatory agencies-including the U.S. FDA, the European EMA, and Hong Kong’s Department of Health-for the following indications:
In practice, metformin is most often prescribed to adults with inadequate glycemic control from diet and exercise alone. It is also recommended for patients with obesity-related insulin resistance, where weight-neutral or modest weight-loss benefits are desirable.
Metformin has been studied for several off-label applications that show promise in peer-reviewed research:
Off-label disclaimer: Off-label use of metformin requires medical supervision and individualized risk assessment.
Absolute contraindications
Relative contraindications
Special populations
Patients should inform their healthcare provider of all medicines, supplements, and herbal products before starting metformin.
Standard dosing:
Initiate therapy with 500 mg once daily (usually with the evening meal).
Titrate upward by 500 mg weekly or every two weeks, based on tolerability and glycemic response.
Typical maintenance dose ranges from 1500 mg to 2000 mg daily, divided into two doses (e.g., 500 mg + 1000 mg).
The maximum recommended dose for most patients is 2500 mg per day (alternative regimens may allow up to 2550 mg).
Special populations:
Renal impairment: If eGFR 30-45 mL/min/1.73 m², limit total daily dose to 1000 mg and monitor renal function every 3-6 months.
Hepatic disease: Start at the lower dose (500 mg) and titrate cautiously.
Elderly: Consider starting at 500 mg once daily and adjust based on renal function.
Administration tips:
Swallow tablets whole; do not crush or chew.
Take with a full glass of water, preferably with food.
If a dose is missed, take it as soon as remembered with the next meal; do not double up.
Overdose:
Symptoms may include nausea, vomiting, abdominal pain, and profound lactic acidosis.
Seek emergency medical care; supportive care and correction of acid-base imbalance are the mainstays.
Discontinuation:
No tapering is required for metformin itself, but abrupt cessation may lead to loss of glycemic control.
If switching to another antidiabetic agent, coordinate timing with a healthcare professional to avoid hyperglycemia or hypoglycemia.
This article provides educational information about metformin and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Metformin is contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73 m²). For mild to moderate reduction (eGFR 30-45 mL/min/1.73 m²), a reduced dose (typically ≤ 1000 mg daily) may be prescribed, with frequent monitoring of renal function.
Taking metformin with the largest meal of the day-usually dinner-helps minimize gastrointestinal side effects. If divided doses are used, the first dose is commonly taken with dinner and the second with breakfast.
Take the missed dose with the next main meal, regardless of the new local time. Avoid taking two doses close together; simply resume the regular dosing schedule based on meal times.
Generic metformin tablets share the same active ingredient but may vary in fillers, binders, or dyes. These differences are generally clinically insignificant, though patients with specific allergies should review the excipient list.
Metformin can be used cautiously in stable chronic heart failure if renal function is adequate. Unstable or acute decompensated heart failure is a relative contraindication due to the heightened risk of lactic acidosis.
Moderate alcohol consumption is permissible, but excessive intake should be avoided because it can increase the risk of lactic acidosis and worsen glycemic control.
Prescriptions for metformin in Hong Kong are typically issued for 30- or 90-day supplies, depending on the prescriber’s assessment and pharmacy policies. Refill intervals should align with routine monitoring appointments.
Symptoms may include fatigue, tingling or numbness in the hands and feet, and mild anemia. Regular blood tests can detect early deficiency, allowing for supplementation if needed.
Immediate-release tablets are taken twice daily and may cause more gastrointestinal upset. Extended-release tablets are taken once daily, often with better tolerability, but dosing flexibility differs. Both forms contain the same active ingredient.
While some studies show modest weight reduction, metformin is not approved for weight management in people without diabetes. Use for this purpose should only be considered under specialist supervision after evaluating risks and benefits.
